Aclaris Therapeutics, Inc. (ACRS)
Summary
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aclaris Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 9 | $27.78 | $34.2 | $6.42 | 23.11% |
| NA Nizar Araji National Bank Of Canada /FI/ | 102 | $512.04 | $386.07 | -$125.97 | -24.6% |
| BG Bart Gancher Intech Investment Management LLC | 24,668 | $66,973.94 | $94,387.17 | $27,413.23 | 40.93% |
| MM Mike Muhizi SG Americas Securities LLC | 34,814 | $108,522.17 | $129,821.41 | $21,299.24 | 19.63% |
| CD Charlie Durham Sterling Capital Management LLC | 3,657 | $16,931.01 | $13,951.45 | -$2,979.56 | -17.6% |
Aclaris Therapeutics, Inc. (ACRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aclaris Therapeutics, Inc. ever had a stock split?
Aclaris Therapeutics, Inc. Profile
| Professional Services Industry | Industrials Sector | Neal S. Walker CEO | NASDAQ (NGS) Exchange | 00461U105 CUSIP |
| US Country | 71 Employees | - Last Dividend | - Last Split | 7 Oct 2015 IPO Date |
Overview
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for immune-inflammatory diseases. The company, founded in 2012 and based in Wayne, Pennsylvania, operates within the United States across two main segments: Therapeutics and Contract Research. The Therapeutics segment is focused on identifying and developing innovative therapies aimed at meeting the significant unmet needs in immuno-inflammatory diseases. Meanwhile, the Contract Research segment offers laboratory services, supporting the broader research and development efforts within the field.
Products and Services
- Zunsemetinib (ATI-450)
An MK2 inhibitor currently under Phase 1b/2 trials designed for the treatment of metastatic breast and pancreatic cancer. Zunsemetinib aims to address critical gaps in the treatment of these widespread and deadly cancers by targeting and inhibiting specific molecular pathways associated with tumor growth and spread.
- ATI-1777
A soft JAK 1/3 inhibitor that has completed Phase 2b trials for the treatment of moderate to severe atopic dermatitis, among other dermatologic conditions. ATI-1777 represents a novel approach in managing dermatologic conditions by modulating the immune response, potentially offering a therapeutic alternative for patients with limited treatment options.
- ATI-2138
An oral covalent inhibitor of ITK and JAK3, currently under Phase 1 trials as a potential treatment for T cell-mediated autoimmune diseases. ATI-2138 works by inhibiting specific enzymes involved in the activation of T cells, part of the immune system's response that can cause harmful inflammation in autoimmune diseases.
Contact Information
